Tirzepatide – (3ml Pen)
The dual-agonist that redefined the category. A single molecule engineered to engage two incretin receptors simultaneously. Research use only.
Incretin Pathway
Metabolic Regulation
Glucose Signalling
Description
Tirzepatide marked a structural shift in incretin research — a single engineered peptide acting at two receptors rather than one. The dual GIP and GLP-1 agonist approach produced trial results that forced a re-evaluation of what the category could achieve, and the compound has since become the benchmark against which subsequent multi-agonist designs are measured. The literature is large, recent, and dominated by well-powered clinical work.
Mechanisms of Action
Tirzepatide is a synthetic 39-amino-acid peptide based on the native GIP sequence, engineered for balanced agonism at both the GIP and GLP-1 receptors and acylated with a C20 fatty diacid for albumin binding and extended half-life. Research describes complementary signalling through the two receptor populations: GLP-1 receptor activity affecting insulin secretion, glucagon suppression and satiety, and GIP receptor activity additionally implicated in adipose tissue metabolism and nutrient handling. The relative contribution of the GIP arm remains an active area of mechanistic debate in the literature.
Research Status & Findings
Clinical characterisation is extensive and the mechanistic literature is developing quickly, particularly around the still-contested role of GIP receptor agonism in the compound's observed effects.
Comparative research
Head-to-head trial data against single-agonist GLP-1 compounds.
Metabolic endpoints
Investigation of glycaemic control and body composition across large cohorts.
Mechanistic debate
Ongoing research into whether GIP receptor agonism or antagonism drives observed effects.
Adipose tissue research
Studies on GIP receptor expression and lipid handling in adipocytes.
Intellectual property
This compound sits within an active and heavily defended patent landscape.
*For research purposes only – not for human consumption*
As Seen In The Press
Peptides can affect the way the body functions at a cellular level.
Our 3 Step System
Pre-filled Cartridges
Engineered for absolute accuracy and ease. Our pre-blended pens make precise dosing completely seamless in just three quick steps.
Step 1 - Remove the Pre-mixed pen from the box
Step 2 - Secure the needle tip
Step 3 - Twist to set the required dose
Blends
Blends
Sermorelin + GHRP-6 – 5mg / 5mg (3ml Pen)
Sermorelin + GHRP-6 5mg/5mg combines a 29-amino-acid GHRH analogue with a synthetic ghrelin receptor agonist. Investigated for complementary growth hormone signalling pathways, pituitary hormone. Research use only.
£95.00
Blends
Sermorelin + GHRP-2 – 5mg / 5mg (3ml Pen)
Sermorelin + GHRP-2 5mg/5mg combines a 29-amino-acid GHRH analogue with a synthetic growth hormone secretagogue. Investigated for complementary pituitary signalling, ghrelin receptor activation and. Research use only.
£99.00
Blends
Longevity Blend (Glutathione / NAD+ / Resveratrol) – 500mg / 100mg / 500mg (3ml Pen)
Three pillars of cellular ageing research in one pen. Pairs antioxidant defence, NAD+ coenzyme power, and sirtuin-modulating activity. Research use only. Research use only.
£129.00
Blends
Vitality Blend (Glutathione / NMN / Resveratrol) – 500mg / 500mg / 500mg (3ml Pen)
The NAD+ precursor evolution. Swaps direct NAD+ for NMN — the biosynthetic precursor the cell uses via the salvage pathway. Research use only. Research use only.
£129.00
Blends
SS-31 + MOTS-c – 10mg / 10mg (3ml Pen)
Two mitochondrial compounds acting on different layers of the same biology — membrane structure and mitokine signalling. Research use only. Research use only.
£139.00
Blends
SS-31 + MOTS-c + NAD+ – 10mg / 10mg / 200mg (3ml Pen)
The flagship triple combination of mitochondrial research. SS-31, MOTS-c and NAD+ each act on a different layer of cellular energy biology — structure, signal. Research use only.
£159.00
Blends
KLOW Blend Peptide – BPC-157, TB-500, KPV & GHK-Cu (3ml Pen)
KLOW Blend Peptide combines BPC-157 10mg, TB-500 10mg, KPV 10mg and GHK-Cu 50mg in a four-component research formulation. The blend brings together compounds studied. Research use only.
£105.00
Blends
CJC-1295 (No DAC) + Ipamorelin + GHRP-2 – 3mg / 3mg / 3mg (3ml Pen)
A three-component preparation pairing a GHRH analogue with both a selective and a higher-potency ghrelin agonist. Research use only. Research use only.
£95.00
Blends
Glow Blend Peptide – BPC-157, TB-500 & GHK-Cu (3ml Pen)
Glow Blend Peptide combines GHK-Cu 50mg, BPC-157 10mg and TB-500 10mg in a three-component research formulation. Its ingredients have been investigated individually for extracellular. Research use only.
£95.00